Impact Pronostique d'un événement Rythmique Ventriculaire Durant le Port de la LifeVest en Post-infarctus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Infarction, Myocardial
- Sponsor
- Mathieu ECHIVARD
- Enrollment
- 1032
- Locations
- 39
- Primary Endpoint
- Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Sudden death from ventricular arrhythmia is a serious and common complication of myocardial infarction, especially with low left ventricular ejection fraction (LVEF). Implantable cardiac defibrillator (ICD) implantation is currently recommended at three months of optimal medical treatment in patients who have had a myocardial infarction and have a LVEF below 35%. This strategy indeed allows a reduction in mortality while early post-infarction implantation showed no benefit in terms of survival. However, the risk of sudden death at this period is the greatest and the temporary defibrillator vest, marketed under the name LifeVest, is now indicated in the early post-infarction period in patients with LVEF less than 35%. Indeed, the LifeVest would allow a reduction in sudden death of rhythmic origin in the first three months post-infarction. No study has yet investigated the prognostic significance of a ventricular rhythm disorder (ventricular tachycardia [VT] or ventricular fibrillation [VF]) occurring during this early and short (approximately 3 months) particular period of wearing the LifeVest: is this a random event, or is it an event predictive of a rhythmic recurrence? The aim of the study is to assess the association between the occurrence of a sustained ventricular rhythm disorder in the early post-infarction period, during the period of wearing the LifeVest (ventricular episodes detected, treated or not), and the risk of rhythmic recurrence at 12 months.
Investigators
Mathieu ECHIVARD
Principal Investigator
Central Hospital, Nancy, France
Eligibility Criteria
Inclusion Criteria
- •Adult patients who benefited, between the start of 2015 and January 1, 2021, from a LifeVest after a myocardial infarction, followed by the implantation of an ICD before March 1, 2021.
Exclusion Criteria
- •Patient opposition to the use of their data.
Outcomes
Primary Outcomes
Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.
Time Frame: 12 months after ICD implantation
Secondary Outcomes
- Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD.(Up to 7 years after ICD implantation)
- Rate of need to set-up left ventricular assist device (LVAD) or heart transplantation.(: 12 months and up to 7 years after ICD implantation)
- Rate of all-cause death.(12 months and up to 7 years after ICD implantation)
- Rate of rhythmic storm defined by ACC / AHA / ESC 2006 guidelines (≥3 episodes of VF, sustained VT or appropriate shock in 24 hours).(12 months and up to 7 years after ICD implantation])
- Rate of hospitalization for heart failure worsening.(12 months and up to 7 years after ICD implantation)
- Rate of rhythmic recurrence defined as the occurrence of a sustained or treated ventricular rhythm disorder (VT or VF) during monitoring of the ICD, and mortality from any cause.(12 months and up to 7 years after ICD implantation)